Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiple TCR-T therapy candidates for the treatment of various solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

15 Jul '21
WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public...
27 May '21
Bill Desmarais, Ph.D., MBA, named Chief Business Officer, bringing more than 20 years of business development and partnering experience Oncology drug development veteran Gabriela Gruia, M.D., appointed to Board of Directors Timothy Barberich named Chair of Board of Directors WALTHAM, Mass., May 27,...

Events

More events are coming soon.

SEC Filings

Filing date Description Form

Initial filing by director officer or owner of more than ten percent.

3

Initial filing by director officer or owner of more than ten percent.

3

Initial filing by director officer or owner of more than ten percent.

3